Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 4/20 | 0.55 |
| ▸ | TTR | P02766 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952242 | 1.00 | ENPP2 (0.55) | ENPP2TTRCA2CA1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL994032 | 0.98 | ENPP2 (0.53) | ENPP2TTRCA2CA1ALDH1A1 | |
| SCHEMBL14421550 | 0.81 | KMT2A (0.37) | ENPP2ALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL12419218 | 0.77 | KMT2A (0.39) | ENPP2ALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL360458 | 0.75 | NPC1 (0.57) | ENPP2CA2CA1ALDH1A1MAPT | |
| SCHEMBL3719246 | 0.75 | ALDH1A1 (0.39) | ENPP2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL317300 | 0.75 | ALDH1A1 (0.58) | ENPP2CA2CA1ALDH1A1MAPT | |
| SCHEMBL29952779 | 0.75 | NPC1 (0.57) | ENPP2CA2CA1ALDH1A1MAPT | |
| SCHEMBL29953773 | 0.74 | ENPP2 (0.43) | ENPP2TTRCA2CA1MAPT | |
| Hydrochloric Acid SCHEMBL12506154 | 0.74 | ALDH1A1 (0.56) | ENPP2CA2CA1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11495769-B2 | Inorganic light emitting diode and inorganic light emitting device including the same | LG DISPLAY CO., LTD. (KR) | 2022-11-08 | — | — | US | claimed |
| US-20210167321-A1 | INORGANIC LIGHT EMITTING DIODE AND INORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | LG DISPLAY CO., LTD. (KR) | 2021-06-03 | — | — | US | claimed |
| CN-119707864-A | Compound, luminescent layer main body material and organic electroluminescent device | 北京师范大学 | 2025-03-28 | — | — | CN | disclosed |
| WO-2024253416-A1 | PYRIMIDINE/PYRIDINE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2024-12-12 | — | — | WO | disclosed |
| EP-4447963-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240336568-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | US | disclosed |
| CN-118715015-A | Selective PHD1 inhibitor compounds, compositions and methods of use | 阿克比治疗有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-113906022-B | Pyrazolopyridines and triazolopyridines as A2A/A2B inhibitors | 因赛特公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-115504973-B | Benzisoxazole compound, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2024-05-14 | — | — | CN | disclosed |
| US-20240101577-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2024-03-28 | — | — | US | disclosed |
| EP-3917925-B1 | PYRAZOLOPYRIDINES AND TRIAZOLOPYRIDINES AS A2A / A2B INHIBITORS | INCYTE CORP (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20110312903-A1 | FLUORINATION OF ORGANIC COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2011-12-22 | — | — | US | disclosed |
| EP-2376408-A2 | FLUORINATION OF ORGANIC COMPOUNDS | President and Fellows of Harvard College (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2011-07-28 | — | — | US | disclosed |
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2011-07-28 | — | — | US | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135524-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010059943-A2 | FLUORINATION OF ORGANIC COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010052448-A2 | FUSED PYRAZINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | ENPP2 1476/4885TTR 4875/4885CA2 428/4885 |
| US-20110312903-A1 | FLUORINATION OF ORGANIC COMPOUNDS | SLCO1B3, SLCO2B1, FLI1 | ENPP2 3381/4885TTR 1736/4885CA2 2244/4885 |
| US-20240101577-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN18, PTPN1, PTPRJ | ENPP2 162/4885TTR 1901/4885CA2 2642/4885 |
| US-20110190489-A1 | Novel Tricyclic Compounds | CCNI, IL2, IL4I1 | ENPP2 1418/4885TTR 2652/4885CA2 1319/4885 |
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, ARAF, NRAS | ENPP2 3407/4885TTR 2800/4885CA2 2675/4885 |
| US-20240336568-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN1, EGLN2 | ENPP2 2134/4885TTR 4577/4885CA2 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.